These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 15592581)
21. Aripiprazole: profile on efficacy and safety. Goodnick PJ; Jerry JM Expert Opin Pharmacother; 2002 Dec; 3(12):1773-81. PubMed ID: 12472374 [TBL] [Abstract][Full Text] [Related]
22. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. DeLeon A; Patel NC; Crismon ML Clin Ther; 2004 May; 26(5):649-66. PubMed ID: 15220010 [TBL] [Abstract][Full Text] [Related]
23. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Naber D; Lambert M Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1213-9. PubMed ID: 15588748 [TBL] [Abstract][Full Text] [Related]
24. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Shapiro DA; Renock S; Arrington E; Chiodo LA; Liu LX; Sibley DR; Roth BL; Mailman R Neuropsychopharmacology; 2003 Aug; 28(8):1400-11. PubMed ID: 12784105 [TBL] [Abstract][Full Text] [Related]
25. Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy. Cassano GB; Fagiolini A; Lattanzi L; Monteleone P; Niolu C; Sacchetti E; Siracusano A; Vita A Clin Drug Investig; 2007; 27(1):1-13. PubMed ID: 17177576 [TBL] [Abstract][Full Text] [Related]
26. Aripiprazole: does partial dopaminergic agonism translate into clinical benefits? Crismon ML; DeLeon A; Miller AL Ann Pharmacother; 2003 May; 37(5):738-40. PubMed ID: 12708954 [No Abstract] [Full Text] [Related]
27. Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Wood M; Reavill C Expert Opin Investig Drugs; 2007 Jun; 16(6):771-5. PubMed ID: 17501690 [TBL] [Abstract][Full Text] [Related]
28. Intramuscular aripiprazole : a review of its use in the management of agitation in schizophrenia and bipolar I disorder. Sanford M; Scott LJ CNS Drugs; 2008; 22(4):335-52. PubMed ID: 18336061 [TBL] [Abstract][Full Text] [Related]
30. Aripiprazole: a review of its pharmacology and clinical use. Taylor DM Int J Clin Pract; 2003; 57(1):49-54. PubMed ID: 12587943 [TBL] [Abstract][Full Text] [Related]
31. Biological perspectives. Aripiprazole: a third generation of antipsychotics begins? Keltner NL; Johnson V Perspect Psychiatr Care; 2002; 38(4):157-9. PubMed ID: 12629954 [TBL] [Abstract][Full Text] [Related]
32. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772 [TBL] [Abstract][Full Text] [Related]
33. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Grunder G; Carlsson A; Wong DF Arch Gen Psychiatry; 2003 Oct; 60(10):974-7. PubMed ID: 14557141 [TBL] [Abstract][Full Text] [Related]
34. Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole. De Berardis D; Fornaro M; Serroni N; Marini S; Piersanti M; Cavuto M; Valchera A; Mazza M; Girinelli G; Iasevoli F; Perna G; Martinotti G; Di Giannantonio M Recent Pat Endocr Metab Immune Drug Discov; 2014 Jan; 8(1):30-7. PubMed ID: 24372345 [TBL] [Abstract][Full Text] [Related]